ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells

被引:36
作者
Giannelli, G
Azzariti, A
Sgarra, C
Porcelli, L
Antonaci, S
Paradiso, A
机构
[1] Univ Bari, Sch Med, Dept Internal Med, Sect Internal Med, Bari, Italy
[2] NCI, Clin Expt Oncol Lab, Bari, Italy
关键词
hepatocellular carcinoma; Laminin-5; ZD6474; extracellular matrix proteins; vascular endothelial growth factor; receptor; biological therapies; invasion; proliferation;
D O I
10.1016/j.bcp.2005.11.005
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Hepatocellular carcinoma (HCC) is characterized by hypervascularization, neoangiogenesis formation and blood vessel invasion. Recently, it has been demonstrated that an inhibitor of the vascular endothelial growth factor (VEGF) receptor, ZD6474, may directly inhibit the growth of tumor cells. ZD6474 effectiveness was investigated on cell growth, apoptosis, adhesion, migration and invasion and related to the drug-dependent modulation of main molecular targets on HCC cells. ZD6474 inhibited HCC cell proliferation, however, such effect was reverted by Laminin-5 (Ln-5) but not by other extracellular matrix proteins (ECM). ZD6474 also inhibited HCC cell adhesion, migration and invasion, whereas the simultaneous treatment with the drug and Ln-5 strongly recovered those effects. Under the same experimental conditions, ZD6474 inhibited the expression of phosphorylated EGFR in all cell lines while the effect on p-Erk1/2 was dependent on cellular invasive characteristics. Nonetheless, co-incubation with Ln-5 completely recovered this effect. Our results support the hypothesis that ZD6474 could represent an interesting therapeutic opportunity for patients with HCC scarcely expressing the ECM protein, Ln-5. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:479 / 485
页数:7
相关论文
共 38 条
[1]
ALBINI A, 1987, CANCER RES, V47, P3239
[2]
Focus on hepatocellular carcinoma [J].
Bruix, J ;
Boix, L ;
Sala, M ;
Llovet, JM .
CANCER CELL, 2004, 5 (03) :215-219
[3]
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer [J].
Carlomagno, F ;
Santoro, M .
JOURNAL OF CHEMOTHERAPY, 2004, 16 :49-51
[4]
Angiogenesis in health and disease [J].
Carmeliet, P .
NATURE MEDICINE, 2003, 9 (06) :653-660
[5]
Ciardiello F, 2003, CLIN CANCER RES, V9, P1546
[6]
COLOMBO M, 1989, LANCET, V2, P1006
[7]
Involvement of tumor cell integrin αvβ3 in hematogenous metastasis of human melanoma cells [J].
Felding-Habermann, B ;
Fransvea, E ;
O'Toole, TE ;
Manzuk, L ;
Faha, B ;
Hensler, M .
CLINICAL & EXPERIMENTAL METASTASIS, 2002, 19 (05) :427-436
[8]
The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[9]
Giannelli G, 2003, CLIN CANCER RES, V9, P3684
[10]
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells [J].
Giannelli, G ;
Azzariti, A ;
Fransvea, E ;
Porcelli, L ;
Antonaci, S ;
Paradiso, A .
BRITISH JOURNAL OF CANCER, 2004, 91 (11) :1964-1969